Mechanisms of Resistance to KRASG12C Inhibitors
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
KRAS is one of the most common human oncogenes, but concerted efforts to produce direct inhibitors have largely failed, earning KRAS the title of “undruggable”. Recent efforts to produce subtype specific inhibitors have been more successful, and several KRASG12C inhibitors have reached clinical trials, including adagrasib and sotorasib, which have shown early evidence of efficacy in patients. Lessons from other inhibitors of the RAS pathway suggest that the effect of these drugs will be limited in vivo by the development of drug resistance, and pre-clinical studies of G12C inhibitors have identified evidence of this. In this review we discuss the current evidence for G12C inhibitors, the mechanisms of resistance to G12C inhibitors and potential approaches to overcome them. We discuss possible targets of combination therapy, including SHP2, receptor tyrosine kinases, downstream effectors and PD1/PDL1, and review the ongoing clinical trials investigating these inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“These compounds rely on mutant cysteine for binding, disrupting Switch-I/II and converting KRAS preference from GTP to GDP, thus holding KRAS in the inactive GDP bound state [29].”
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 7×
“[27] found that AMG-510 led to a pro-inflammatory tumour microenvironment and acted synergistically with immune checkpoint inhibitors.”
BackgroundInfluentialUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“GEFs stimulate the dissociation of GDP and subsequent association of GTP, activating RAS proteins, while GAPs act to accelerate intrinsic GTP hydrolysis, converting RAS to its inactive state [2,3].”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · cited 1×
“9 months in patients with NSCLC receiving standard 2nd or 3rd line chemotherapy [36]).”
BackgroundSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · cited 1×
“Missense mutations at codons 12 and 13 are thought to limit interaction of GAP proteins with the GTPase site of RAS proteins, preventing their hydrolysis to an inactive state [8].”
Background
Research works printed but not linked: 21
- Pakkala, 2018, Personalized therapy for lung cancer: Striking a moving target, JCI Insight, 3, 120858, 10.1172/jci.insight.120858 · DOI · Paper page
- Wang, 2012, Ras inhibition via direct Ras binding—Is there a path forward?, Bioorganic Med. Chem. Lett., 22, 5766, 10.1016/j.bmcl.2012.07.082 · DOI · Paper page
- Lindsay, 2018, KRAS: Reasons for optimism in lung cancer, Eur. J. Cancer, 99, 20, 10.1016/j.ejca.2018.05.001 · DOI · Paper page
- Ahearn, 2011, Regulating the regulator: Post-translational modification of RAS, Nat. Rev. Mol. Cell Biol., 13, 39, 10.1038/nrm3255 · DOI · Paper page
- Brunner, 2003, Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations, Cancer Res., 63, 14522880
- Kohl, 1995, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice, Nat. Med., 1, 792, 10.1038/nm0895-792 · DOI · Paper page
- Heymach, 2004, Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer, Ann. Oncol., 15, 1187, 10.1093/annonc/mdh315 · DOI
- Ho, 2018, Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations, Ann. Oncol., 29, viii373, 10.1093/annonc/mdy287.002 · DOI
- Burrows, 2020, Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma, Eur. J. Cancer, 138, S43, 10.1016/S0959-8049(20)31191-6 · doi:10.1016/s0959-8049(20)31191-6
- Lindsay, 2019, Direct Ras G12C inhibitors: Crossing the rubicon, Br. J. Cancer, 121, 197, 10.1038/s41416-019-0499-1 · DOI · Paper page
- Hayashi, 2013, Postprogression Survival in Patients with Advanced Non–Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy, Clin. Lung Cancer, 14, 261, 10.1016/j.cllc.2012.09.006 · DOI
- Franke, 2008, PI3K/Akt: Getting it right matters, Oncogene, 27, 6473, 10.1038/onc.2008.313 · DOI · Paper page
- Singh, 2009, A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page
- Little, 2011, Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells, Sci. Signal., 4, ra17, 10.1126/scisignal.2001752 · DOI · Paper page
- Corcoran, 2012, EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib, Cancer Discov., 2, 227, 10.1158/2159-8290.CD-11-0341 · DOI · Paper page
- Bendell, 2020, Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling, Eur. J. Cancer, 138, S8, 10.1016/S0959-8049(20)31089-3 · DOI
- Fedele, C., Li, S., Teng, K.W., Foster, C.J., Peng, D.H., Ran, H., Mita, P., Geer, M.J., Hattori, T., and Koide, A. (2021). SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J. Exp. Med., 218. · DOI · Paper page
- Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat. Med., 14, 1351, 10.1038/nm.1890 · DOI · Paper page
- Alagesan, 2015, Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer, Clin. Cancer Res., 21, 396, 10.1158/1078-0432.CCR-14-1591 · DOI · Paper page
- Juric, 2014, A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors, J. Clin. Oncol., 32, 9051, 10.1200/jco.2014.32.15_suppl.9051 · DOI · Paper page
- Foster, 2014, Metabolic vulnerability of KRAS-driven cancer cells, Mol. Cell. Oncol., 1, e963445, 10.4161/23723548.2014.963445 · DOI
Cited by
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Reck, M., Carbone, D. P., Garassino, M., & Barlesi, F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.001 · Cited by 326
Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-22668-1 · Cited by 93
“Nineteen (19) compounds were selected and further subjected to docking using GLIDE docking suit incorporated in Schrödinger with an extra precision (XP).”
MethodOncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Metadata
- Authors
- Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-05
- Volume
- 13
- Issue
- 1
- Pages
- 151
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3119145039
- Cited by
- 117
- References
- 55
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Cancer Research UK (A25254, A20465)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of Resistance to KRASG12C Inhibitors. https://app.cochat.ai/papers/10.3390/cancers13010151
- The paper
- Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021). Mechanisms of Resistance to KRASG12C Inhibitors. Cancers. https://doi.org/10.3390/cancers13010151
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.